Testing the drug Lutathera in young people whose high-grade brain or spine tumor has come back or grown
Official title: Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether a drug called Lutathera is safe, and whether it helps young people whose brain or spine tumor has come back or is growing.
Read our full plain-language summary
What the trial team says
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively. Funding Source - FDA OOPD (grant number FD-R-0532-01)
Key facts
- Registry number
- NCT05278208
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Where it is running
This trial lists 4 sites.
-
Colorado
- Children's Hospital Colorado (Aurora)
-
Ohio
- Cincinnati Children's Hospital Medical Center (Cincinnati)
- Nationwide Children's Hospital (Columbus)
-
Pennsylvania
- Children's Hospital of Philadelphia (Philadelphia)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.